Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Annals of Oncology
Open Access 
Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group

Authors: D. Mandelker, M. Donoghue, S. Talukdar, M.F. Berger, B.S. Taylor, C. Turnbull
Show all authors

DOI: https://doi.org/10.1093/annonc/mdz136

Abstract

It is increasingly common in oncology practice to perform tumour sequencing using large cancer panels. For pathogenic sequence variants in cancer susceptibility genes identified on tumour-only sequencing, it is often unclear whether they are of somatic or constitutional (germline) origin. There is wide-spread disparity regarding both the extent to which systematic ‘germline-focussed analysis’ is carried out upon tumour sequencing data and for which variants follow-up analysis of a germline sample is carried out.

Here we present analyses of paired sequencing data from 17152 cancer samples, in which 1494 pathogenic sequence variants were identified across 65 cancer susceptibility genes.

From these analyses, the European Society of Medical Oncology Precision Medicine Working Group Germline Subgroup has generated (i) recommendations regarding germline-focussed analyses of tumour-only sequencing data, (ii) indications for germline follow-up testing and (iii) guidance on patient information-giving and consent.

Read full text article in Annals of Oncology

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings